K22291048计算溶液所需的质量、体积或浓度。
为什么选择此级别
提供 ≥98% 纯度，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-20°C储存,充氩。超低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
Information
TAS-102 TAS-102 (Trifluridine-Tipiracil Hydrochloride Mixture) is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine , and a thymidine phosphorylase inhibitor, tipiracil hydrochloride .
In vitro
TAS-102 is an oral combination drug consisting of trifluridine (FTD), which is a thymidine-based nucleoside analog, and tipiracil hydrochloride (TPI), which improves the bioavailability of FTD by inhibiting its catabolism by thymidine phosphorylase (TP). Phosphorylated form of trifluridine is incorporated into DNA resulting in DNA dysfunction and cell cycle arrest. Thymidine phosphorylase inhibitor inhibits degradation of FTD and inhibits angiogenesis. Thus, TAS-102 treatment results in massive trifluridine incorporation into DNA and in activation of similar DNA damage response pathways, which involve phosphorylation of Chk1 and cycle arrest during the G2/M-phase.
In vivo
The elimination half-life of FTD after intravenous administration to humans is very rapid (18 minutes), due to the rapid degradation of FTD to its major metabolite, 5-trifluoromethyl-2,4(1H,3H)-pyrimidinedione. In monkeys, the plasma FTD level after oral administration alone is very low, suggesting extensive first-pass metabolism by the liver and intestine TPase. However, the addition of TPI(tipiracil hydrochloride) is found to enable oral administration. By inhibiting TP, TPI inhibits the degradation of FTD in the liver and intestines following oral administration and thereby improves its bioavailability. The TP enzyme catalyzes the phosphorolysis of pyrimidine 2\'-deoxynucleosides such as FTD. Studies using human CRC tumor xenografts in mice determine that the maximum antitumor activity is achieved with a 1:0.5 molar ratio, and studies in mice and monkeys show that the maximum plasma concentration of FTD is almost achieved with the same ratio. Moreover, this ratio produces a favorable balance between antitumor activity and toxicity. Lower toxicity in mice is observed with TPI coadministration than with FTD alone. TAS-102 (FTD) can overcome acquired resistance to 5-FU because the main mechanism of TAS-102 is not associated with main metabolic enzymes of 5-FU, such as TS and OPRT. TAS-102 has demonstrated efficacy in 5-FU-refractory cancers.
规格
英文别名
Tipiracil-trifluridine Mixture (2:1) | trifluridine (TFT) and Tipiracil Hydrochloride (TTP) in molar ratio of 1: 0.5 | Trifluridine-tipiracil Hydrochloride Mixture | Trifluridine-Tipiracil Hydrochloride MixtureThymidine,α,α,α-trifluoro-,mixt. with 5-
规格或纯度
≥98%
英文名称
TAS-102
生化机理
TAS-102（三氟尿苷-盐酸替吡嘧啶混合物）是胸腺嘧啶核酸类似物三氟尿苷和胸腺嘧啶磷酸化酶抑制剂盐酸替吡嘧啶的口服复方制剂。
储存条件
-20°C储存,充氩
运输条件
超低温运输
纯度
≥98%
名称和识别符
分子类型
小分子
Smiles
Cl.OCC1OC(CC1O)N2C=C(C(=O)NC2=O)C(F)(F)F.OCC3OC(CC3O)N4C=C(C(=O)NC4=O)C(F)(F)F.ClC5=C(CN6CCCC6=N)NC(=O)NC5=O
分子量
871.52
技术文档
高级数据
化学和物理性质
溶解性
Solubility (25°C) In vitro DMSO: 100 mg/mL warmed with 50ºC Water: bath (114.74 mM); Ethanol: 100 mg/mL (114.74 mM); Water: 15 mg/mL warmed with 50ºC Water: bath (17.21 mM);
敏感性
易吸潮
安全和危险性（GHS）
象形图
信号词
警告
危险声明
H302: 吞食有害
H315: 引起皮肤刺激
H319: 引起严重眼睛刺激
H335: 可能引起呼吸道刺激
预防措施声明
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾
P305+P351+P338: 如进入眼睛：用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出，取出隐形眼镜。继续冲洗。
质检证书（CoA,COO,BSE/TSE 和分析图谱)
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）